news aktuell GmbH

Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research

Share

Aachen, Germany – 7 July 2022

Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, Lichtenberg-Professor for Chemosensation at the RWTH Aachen University. The partners strive to develop a range of translational research tools and humanised preclinical models to enhance target validation.

Under the terms of the agreement, Grünenthal will support the institutes led by Professor Lampert and Professor Spehr with approximately € 1 million of funding. Part of the funding allows for establishing two new post-doc positions. The exploratory efforts at the Uniklinik RWTH Aachen and RWTH Aachen University will, if successful, enable their subsequent integration into drug development activities at Grünenthal.

Chronic pain is a considerable burden that impacts up to one in five people worldwide[1]. As one of the most common reasons people seek medical help[2], it affects health care systems and economies, significantly contributing to disability retirement.[3] Various indications come under the umbrella of chronic pain, and patients frequently experience limited efficacy from available medicines.

Despite extensive research, limited progress has been made to bring new medicines that address this unmet medical need. Scientists have used rodent models to investigate the cellular and molecular mechanisms involved in pain. However, the successful translation of these preclinical findings into new treatments for patients with chronic pain has proven difficult. The pathophysiology of chronic pain depends on a range of aspects that have not been well modelled in preclinical species yet, due to fundamental differences in molecular, cellular and genetic mechanisms of pain across species.

“To enhance target validation and translational potential of novel analgesics, we want to address two gaps,” explains Jan Adams, MD, Chief Scientific Officer Grünenthal. “First, we would like to increase our ability to validate our hypothesis in human cells and tissue, and second, we want to create models to investigate cell-to-cell interactions.”

Human Dorsal Root Ganglia represent key communication nodes in transmitting signals from the peripheral somatosensory nervous system to the central nervous system and ultimately the brain, where one perceives the signals as pain. “Investigating high-quality human DRGs will enable us to understand crucial disease mechanisms in neuropathic pain”, says Dr Angelika Lampert, Professor of Physiology, Uniklinik RWTH Aachen. “Furthermore, we will run a comparative approach between human and non-human DRGs. One of our key goals is to identify the best surrogate species for supporting mechanistic translation into the clinic as efficiently as possible.”

Recent scientific progress allows researchers to investigate sensory neurons at the level of an individual cell to analyse the mechanisms involved in pain. “While these insights are beneficial, it remains vital to preserve cell-to-cell interaction in the preclinical setting to appropriately mimic the disease mechanisms in a living organism and receive translatable data”, says Dr Marc Spehr Lichtenberg-Professor for Chemosensation, RWTH Aachen University. “Through this collaboration, we will establish translational models in which we can measure precisely these interactions via specialised electrophysiological methods. These have the potential to improve the reliability of target validation and the quality of compound testing.”

Grünenthal and Professors Spehr and Lampert share a common research interest in pain and neuroscience. Dr Angelika Lampert is a leading researcher in the field of voltage-gated sodium channels, studying the structure and function of these channels and how to possibly prevent peripheral pain by their pharmacological modulation. Dr Marc Spehr is dedicated to investigating how chemical stimuli are transduced into a cell-specific response via complex biochemical signalling cascades and thus built an understanding of how these signalling mechanisms work on a molecular and cellular level.

Grünenthal is a global leader in pain research and management and has delivered six essential treatment options for pain patients in the last decades. Today, the company is dedicated to creating innovative non-opioid pain treatments that address unmet medical needs. For R&D, Grünenthal executes a distinctive therapeutic area strategy and focuses its efforts on four key pain indications: peripheral neuropathic pain, chronic post-surgical pain, chronic low back pain, and osteoarthritis.

[1]Treede et al Pain 2015 Jun;156(6):1003-1007.

[2]Breivik, H. et al., Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment, European Journal of Pain 10 (2006) 287–333.

[3]Saastamoinen, P. et al., 2012, Pain and disability retirement: a prospective cohort study.

 

About Uniklinik RWTH Aachen

The Uniklinik RWTH Aachen is a supramaximal care provider that combines patient-oriented medicine and nursing, teaching and research at an international level. With 35 specialist clinics, 30 institutes and six interdisciplinary units, the University Hospital covers the entire medical spectrum. Excellently qualified teams of doctors, nurses and scientists are competently committed to the health of the patients. The bundling of patient care, research and teaching in one central building offers the best conditions for intensive interdisciplinary exchange and close clinical and scientific networking. Around 9.000 employees provide patient-oriented medicine and care according to recognised quality standards. With 1.400 beds, Uniklinik RWTH Aachen treats around 50.000 inpatient and 200.000 outpatient cases per year.

 

About RWTH

RWTH Aachen University exploits strong research networks and the intellectual curiosity of its staff to address bold scientific questions, transfer forefront knowledge and drive innovative discoveries that impact global challenges.The Excellence Initiative of the German federal and state governments provided RWTH with a unique opportunity to boost its research profile by strengthening the natural sciences and fostering interdisciplinary research. Topics include sustainable synthetic fuels, data mining, computational science, production technology, high-performance materials, health, renewable resources and mobility. The University educates over 47,000 students enrolled in 170 courses. This includes more than 13,354 international students from 138 countries.

 

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021 Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

More information: www.grunenthal.com

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal

 

For further information please contact

Christopher Jansen

Communication Business Partner

Grünenthal GmbH

52099 Aachen

Phone: +49 241 569-1428

E-mail: Christopher.Jansen@grunenthal.com

Dr. Mathias Brandstädter

Leiter Stabsstelle Unternehmenskommunikation

Uniklinik RWTH Aachen

Pauwelsstraße 30

52074 Aachen

Tel.: 0241 80-89893

Fax: 0241 80-33-89893

mbrandstaedter@ukaachen.de

kommunikation@ukaachen.de

Thorsten Karbach

Dezernent Presse und Kommunikation

RWTH Aachen University

Templergraben 55

52062 Aachen

Phone: +49 241 80 94323

E-mail: thorsten.karbach@zhv.rwth-aachen.de

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

An ordeal that ends on a plate in a tourist resort: Live transports of calves to the Canary Islands9.8.2022 16:47:11 CEST | Press release

Every week, cattle are shipped to the Canary Islands under unacceptable conditions. These transports are extremely long. The animals stand on the truck for even more than 100 hours non-stop. Now, in summer, sweltering heat must be added as well as poor water supply, no or too little food, bedding of excrements and urine, lack of space, and an acrid ammonia smell. Once on the islands, the animals, only a few months old, await death in the slaughterhouse. A trade that is enhanced by subsidies and slaughter premiums .

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Press release

Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 mil

Make some noise for endangered species: Krombacher and Wacken Open Air present the "Growling Creatures" – the first metal band consisting of endangered animals1.8.2022 10:48:17 CEST | Press release

Krombach / Germany, August1st 2022. What do grey seals, cuckoos, and lynx have in common? They are all rare, European native species whose survival is threatened, and they are part of the "Growling Creatures" - the first metal band consisting of endangered animals. Presented by Krombacher and the legendary metal festival Wacken Open Air (W:O:A), this summer the Growling Creatures are drawing attention to their threat and are making some noise for endangered species. "With Krombacher, we have long been committed to domestic and international species protection projects," says Peter Lemm, Head of Communications of the Krombacher brewery. "As a new partner of the Wacken Open Air, it was important for us to create an authentic connection between our sustainable commitment and entertainment with a twinkle in the eye. The Growling Creatures represent exactly this - as musical newcomers of the year, they deliver the best metal sound for the good cause." Animalistic Metal Sound On their mini-E

R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories19.7.2022 08:00:00 CEST | Press release

Darmstadt, July 19, 2022 – As a fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. The biotechnology company R-Biopharm AG announced today that it has received the CE mark and will begin selling the new, fully automated RIDA®UNITY system for molecular detection of infectious diseases throughout Europe. "With the RIDA®UNITY system, R-Biopharm is purposefully taking the path from a provider of individual solutions to a system provider in the field of molecular diagnostics," stated Christian Dreher, CEO of R-Biopharm. "We are very happy to make this system solution available to all molecular biology laboratories throughout Europe." Unique combination of different tools The RIDA®UNITY system combines the various steps in the analysis of patient samples into an integrated workflow – nucleic acid extraction, PCR setup, subsequent real-time PCR and the evaluation of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom